Kezdőlap › Multiplex mielóma › Utah › Salt Lake City
Multiplex mielóma klinikai vizsgálatok: Salt Lake City, UT
21 Multiplex mielóma vizsgálat keres résztvevőket Salt Lake City és környéke (kb. 30 mérföldes körzetben) helyszínein. Nyissa meg a vizsgálatot, hogy lássa, ki csatlakozhat, és hogyan léphet kapcsolatba a csapattal.
Hivatalos vizsgálati szöveg (angol)
Vizsgálatra keres résztvevőket? Emelje ki az oldal tetején — $99 / 30 nap →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Toborzás folyamatban3. fázis
- Research Site, Salt Lake City
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Toborzás folyamatban1/2. fázis
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban3. fázis
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban3. fázis
- Utah Cancer Specialists, Salt Lake City
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Toborzás folyamatban3. fázis
- LDS Hospital, Salt Lake City
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Toborzás folyamatban3. fázis
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Toborzás folyamatban2. fázis
- Intermountain Healthcare, Salt Lake City
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Toborzás folyamatban3. fázis
- Huntsman Cancer Institute, Salt Lake City
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban2. fázis
- LDS Hospital, Salt Lake City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Toborzás folyamatban1/2. fázis
- Huntsman Cancer Institute /ID# 271618, Salt Lake City
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Toborzás folyamatban2. fázis
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Toborzás folyamatban2. fázis
- Huntsman Cancer Institute, Salt Lake City
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Toborzás folyamatban1/2. fázis
- Research Site, Salt Lake City
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Toborzás folyamatban1. fázis
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Toborzás folyamatban1/2. fázis
- Huntsman Cancer Institute /ID# 272575, Salt Lake City
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Toborzás folyamatban2. fázis
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Toborzás folyamatban1. fázis
- Huntsman Cancer Center Institute University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Toborzás folyamatban1. fázis
- University of Utah, Salt Lake City
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Toborzás folyamatban1/2. fázis
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Toborzás folyamatbanMegfigyeléses tanulmány
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Toborzás folyamatban1. fázis
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Multiplex mielóma vizsgálatok más városokban
- New York City, NY60 tanulmány
- Boston, MA42 tanulmány
- Atlanta, GA42 tanulmány
- Houston, TX38 tanulmány
- Durham, NC37 tanulmány
- Nashville, TN32 tanulmány
- Denver, CO27 tanulmány
- Rochester, MN24 tanulmány
- St. Louis, MO24 tanulmány
- Columbus, OH24 tanulmány
- Baldwin Park, CA23 tanulmány
- Edison, NJ22 tanulmány
Egyéb vizsgálatok: Salt Lake City
- Nem kis sejtes tüdőrák31 tanulmány
- Rák (minden típus)27 tanulmány
- Mellrák27 tanulmány
- Kolorektális rák22 tanulmány
- Tüdőrák21 tanulmány
- Melanóma21 tanulmány
- Áttétes rák20 tanulmány
- Petefészekrák19 tanulmány
- Elhízás18 tanulmány
- Akut mieloid leukémia17 tanulmány
- Szívelégtelenség17 tanulmány
- Prosztatarák15 tanulmány
Forrás: ClinicalTrials.gov, adatok lekérve: 2026. okt. 6.. Minden vizsgálat saját alkalmassági feltételeket határoz meg; a döntést a vizsgálati csapat hozza meg.